doxorubicin hydrochloride (liposomal)
AssetSmall moleculeAlso doxorubicin, DOXIL, CAELYX, DPPG2-TSL-DOX
Topoisomerase II inhibitor and DNA intercalator formulated as an inhalation solution.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- DNA damage response
- Indications
- 19
- Trials
- 1,321
- Developers
- 5
Indications
19Breast cancer
Phase 3TERMINATEDNCT05207514clinicaltrials.gov7 Oct 2026
HIV infection
Phase 3COMPLETEDNCT00002319clinicaltrials.gov7 Oct 2026
Kaposi sarcoma
Phase 3COMPLETEDNCT00002319clinicaltrials.gov7 Oct 2026
16 more
- Targets and what it contains5
- Owner and partners5
- Trials1,321
- Evidence for its targets4
- Competitors12
- Aging relevance1
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 15 sources